Niagen Bioscience Secures First USP Monograph for Nicotinamide Riboside Chloride
Event summary
- Niagen Bioscience's patented Nicotinamide Riboside Chloride (NRCl) now has a published USP monograph, setting a global quality benchmark for the ingredient.
- The monograph establishes concrete quality requirements for NRCl, including identity testing, assay specifications, impurity limits, and contaminant/microbial requirements.
- The monograph is expected to be codified and enforced in October 2026.
- Niagen Bioscience collaborated with USP for six years to develop the monograph.
The big picture
This USP monograph represents a significant validation of Niagen Bioscience's scientific rigor and sets a new standard for quality in the NAD+ supplement industry. While NMN and other NAD+ products lack such a benchmark, this development could further entrench Niagen's leadership in the healthy aging market. The monograph's enforcement in October 2026 will be a key milestone to watch, as it could reshape the competitive landscape.
What we're watching
- Competitive Advantage
- Whether Niagen Bioscience can leverage this USP monograph to solidify its market position against competitors like NMN and NAD+ products.
- Regulatory Enforcement
- The pace at which the USP monograph will be adopted and enforced by regulatory bodies globally.
- Market Differentiation
- How this monograph will influence consumer and industry perception of Niagen's products compared to non-USP-standardized alternatives.